EMA Application withdrawn: Izelvay (avacincaptad pegol) — Astellas Pharma Europe B.V.

View source ↗

Summary

EMA has withdrawn the marketing authorization application for Izelvay (avacincaptad pegol) submitted by Astellas Pharma Europe B.V. for geographic atrophy assoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• Izelvay (avacincaptad pegol)

Snippet

Status: Application withdrawn. Therapeutic area: Macular Degeneration;Geographic Atrophy. MAH: Astellas Pharma Europe B.V.